Pfizer’s First COVID-19 Vaccine Results Might Be Just Days Away - But Patience Could Pay Off
Operation Warp Speed Leader Says Early Data Will Be Slim
Analysts are confident that Pfizer/BioNTech’s mRNA vaccine will prove its safety and efficacy – but waiting a little longer for more robust data could be for the best.
You may also be interested in...
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
After threats to overrule the agency, the Trump administration has indicated that the stricter guidance will be allowed to stand.
The UK's MHRA has granted an emergency authorization to the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.